Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) shares were up 14.1% on Tuesday. The company traded as high as $4.3370 and last traded at $4.3350. 3,693 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 86,805 shares. The stock had previously closed at $3.80.
Analyst Ratings Changes
Separately, Jefferies Financial Group raised shares of Raia Drogasil to a “buy” rating and set a $5.20 price objective for the company in a research report on Sunday. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.20.
Get Our Latest Analysis on RADLY
Raia Drogasil Stock Performance
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. Raia Drogasil had a net margin of 2.99% and a return on equity of 20.12%. The firm had revenue of $2.17 billion for the quarter, compared to the consensus estimate of $2.32 billion. Analysts expect that Raia Drogasil S.A. will post 0.17 earnings per share for the current year.
About Raia Drogasil
Raia Drogasil, now operating under the name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a network of pharmacies offering prescription medicines, over-the-counter drugs, vitamins, personal care products, beauty items and other health-related merchandise.
The company also provides digital purchasing and delivery services through its online channels, supporting customers with prescription fulfillment, health products and related services. Its operations include pharmacy-based healthcare initiatives designed to complement its retail business and improve access to everyday healthcare.
RD Saúde was created in 2011 through the merger of Drogasil and Droga Raia, two established Brazilian pharmacy chains.
See Also
- Five stocks we like better than Raia Drogasil
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
- IonQ’s Bold Expansion Could Leave Shareholders Paying the Price
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
